Weißenborn C - Search Results

1

Mast Cells Retard Tumor Growth in Ovarian Cancer: Insights from a Mouse Model.

Meyer N, Hinz N, Schumacher A, Weißenborn C, Fink B, Bauer M, von Lenthe S, Ignatov A, Fest S, Zenclussen AC. Meyer N, et al. Among authors: weissenborn c. Cancers (Basel). 2023 Aug 26;15(17):4278. doi: 10.3390/cancers15174278. Cancers (Basel). 2023. PMID: 37686555 Free PMC article.

2

GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells.

Weißenborn C, Ignatov T, Poehlmann A, Wege AK, Costa SD, Zenclussen AC, Ignatov A. Weißenborn C, et al. J Cancer Res Clin Oncol. 2014 Apr;140(4):663-71. doi: 10.1007/s00432-014-1598-2. Epub 2014 Feb 11. J Cancer Res Clin Oncol. 2014. PMID: 24515910

3

Depletion of Foxp3+ regulatory T cells but not the absence of CD19+IL-10+ regulatory B cells hinders tumor growth in a para-orthotopic neuroblastoma mouse model.

Weißenborn C, von Lenthe S, Hinz N, Langwisch S, Busse M, Schumacher A, Zenclussen AC, Fest S. Weißenborn C, et al. Int J Cancer. 2022 Dec 1;151(11):2031-2042. doi: 10.1002/ijc.34262. Epub 2022 Sep 8. Int J Cancer. 2022. PMID: 36054664 Free article.

4

GPER functions as a tumor suppressor in triple-negative breast cancer cells.

Weißenborn C, Ignatov T, Ochel HJ, Costa SD, Zenclussen AC, Ignatova Z, Ignatov A. Weißenborn C, et al. J Cancer Res Clin Oncol. 2014 May;140(5):713-23. doi: 10.1007/s00432-014-1620-8. Epub 2014 Feb 20. J Cancer Res Clin Oncol. 2014. PMID: 24553912

5

A minigene DNA vaccine encoding peptide epitopes derived from Galectin-1 has protective antitumoral effects in a model of neuroblastoma.

Liebscher L, Weißenborn C, Langwisch S, Gohlke BO, Preissner R, Rabinovich GA, Christiansen N, Christiansen H, Zenclussen AC, Fest S. Liebscher L, et al. Among authors: weissenborn c. Cancer Lett. 2021 Jul 1;509:105-114. doi: 10.1016/j.canlet.2021.03.020. Epub 2021 Apr 10. Cancer Lett. 2021. PMID: 33848518

6

GPER-1 acts as a tumor suppressor in ovarian cancer.

Ignatov T, Modl S, Thulig M, Weißenborn C, Treeck O, Ortmann O, Zenclussen A, Costa SD, Kalinski T, Ignatov A. Ignatov T, et al. Among authors: weissenborn c. J Ovarian Res. 2013 Jul 13;6(1):51. doi: 10.1186/1757-2215-6-51. J Ovarian Res. 2013. PMID: 23849542 Free PMC article.

7

GPER Promoter Methylation Controls GPER Expression in Breast Cancer Patients.

Weissenborn C, Ignatov T, Nass N, Kalinski T, Dan Costa S, Zenclussen AC, Ignatov A. Weissenborn C, et al. Cancer Invest. 2017 Feb 7;35(2):100-107. doi: 10.1080/07357907.2016.1271886. Epub 2017 Jan 24. Cancer Invest. 2017. PMID: 28118074

8

GPER-1 expression decreases during breast cancer tumorigenesis.

Ignatov T, Weißenborn C, Poehlmann A, Lemke A, Semczuk A, Roessner A, Costa SD, Kalinski T, Ignatov A. Ignatov T, et al. Among authors: weissenborn c. Cancer Invest. 2013 Jun;31(5):309-15. doi: 10.3109/07357907.2013.789901. Cancer Invest. 2013. PMID: 23688258

9

Accumulation of the advanced glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable prognosis in estrogen receptor-negative cases.

Nass N, Ignatov A, Andreas L, Weißenborn C, Kalinski T, Sel S. Nass N, et al. Among authors: weissenborn c. Histochem Cell Biol. 2017 May;147(5):625-634. doi: 10.1007/s00418-016-1534-4. Epub 2016 Dec 23. Histochem Cell Biol. 2017. PMID: 28012130

10

G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer.

Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD, Kalinski T. Ignatov A, et al. Among authors: weissenborn c. Breast Cancer Res Treat. 2011 Jul;128(2):457-66. doi: 10.1007/s10549-011-1584-1. Epub 2011 May 24. Breast Cancer Res Treat. 2011. PMID: 21607586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page